Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Go back to Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Otter Lake Resources, Inc. New (NASDAQ: OTLK) Delayed: 1.58 -0.07 (4.24%)
Previous Close $1.65    52 Week High $0.03 
Open $1.62    52 Week Low $0.01 
Day High $1.66    P/E N/A 
Day Low $1.40    EPS $0.00 
Volume 20,623,167